Data Insights

AAA-603 by Advanced Accelerator Applications for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Metastatic Prostate Cancer: Likelihood of Approval

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Metastatic...

Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer

Data Insights

AAA-603 by Advanced Accelerator Applications for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

AAA-603 by Advanced Accelerator Applications for Metastatic Prostate Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Metastatic Prostate Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Metastatic Prostate Cancer

Data Insights

AAA-603 by Advanced Accelerator Applications for Esophageal Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Esophageal Cancer

Data Insights

AAA-603 by Advanced Accelerator Applications for Neuroblastoma: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Neuroblastoma

Data Insights

AAA-603 by Advanced Accelerator Applications for Glioblastoma Multiforme (GBM): Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Glioblastoma Multiforme (GBM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Glioblastoma Multiforme (GBM)

Data Insights

AAA-603 by Advanced Accelerator Applications for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Gastrointestinal Stromal Tumor (GIST)

Data Insights

AAA-603 by Advanced Accelerator Applications for Head And Neck Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Head And Neck Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Head And Neck Cancer

Data Insights

AAA-603 by Advanced Accelerator Applications for Ovarian Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Ovarian Cancer

Data Insights

AAA-603 by Advanced Accelerator Applications for Lung Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Lung Cancer

Data Insights

Lutetium Lu 177 dotatate by Advanced Accelerator Applications for Pheochromocytoma: Likelihood of Approval

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Pheochromocytoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Dotatate in Pheochromocytoma

Data Insights

FF-10158 by Advanced Accelerator Applications for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

FF-10158 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...

Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

FF-10158 by Advanced Accelerator Applications for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

FF-10158 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

FF-10158 by Advanced Accelerator Applications for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

FF-10158 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Pancreatic Ductal Adenocarcinoma

Data Insights

Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase II for Castration-Resistant...

Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Castration-Resistant Prostate Cancer (CRPC)

Data Insights

Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Hormone-Sensitive...

Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer

Data Insights

Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Neuroendocrine Cancer: Likelihood of Approval

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase I for Neuroendocrine...

Data Insights

Lutetium Lu 177 dotatate by Advanced Accelerator Applications for Small-Cell Lung Cancer: Likelihood of Approval

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Small-Cell Lung...

Data Insights

AAA-603 by Advanced Accelerator Applications for Metastatic Breast Cancer: Likelihood of Approval

AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Metastatic Breast Cancer. According to...